Amplyx Pharmaceuticals Inc.
This article was originally published in Start Up
Executive Summary
Other companies' disappointments could turn out to be blessings for Amplyx Pharmaceuticals. The start-up thinks it has a solution for ADME problems that derail candidates in clinical trials or that lead to side effects and reduced efficacy in marketed drugs. Amplyx believes it can improve problematic small-molecule drugs by extending their half-life without making the compounds too big to be delivered orally.
You may also be interested in...
Start-Up Previews (11/2008)
A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "In Immunotherapy, Finally Time for T Cells?," features profiles of Adaptimmune, Altor BioScience, and Cell Medica. Plus these Start-Ups Across Health Care: Adnavance Technologies, Amplyx Pharmaceuticals, IlluminOss Medical, and KM Medical.
Super-Specialist CROs: Commercializing Pharma R&D Expertise
Outsourcing is not just for mundane pharma services anymore. Increasingly, drugmakers are contracting for specialized R&D assistance they expect to provide strategic as well as tactical advantages.